Quantcast

Latest Mucositis Stories

2014-07-08 23:07:23

Dalton Pharma Services signs agreement with GLyPharma Therapeutics Inc., to provide aseptic fill/finish services and analytical services for FE 203799 for cancer patients. Toronto, Ontario (PRWEB) July 08, 2014 Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Manufacturing Services Agreement with GLyPharma Therapeutics Inc., a specialty pharma company based in Montreal,...

2014-07-08 12:28:56

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets DALLAS and NEW YORK, July 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Hong Kong Patent Office that a patent for MuGard(TM) has been granted. The patent (HK1126134) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Being awarded...

2014-06-07 23:01:23

KRS Global Biotechnology (KRS-GBT), premier compounding pharmacy and FDA registered human drug compounding outsourcing facility under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), is excited to announce an addition to their already extensive lines: a compounded oral rinse that may assist with the management of oral mucositis symptoms. Boca Raton, FL (PRWEB) June 07, 2014 KRS Global Biotechnology introduced innovative-compounded oral rinses that may offer a safe...

2014-05-12 08:31:13

PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the first quarter ended March 31, 2014. Soligenix's revenues for the quarter ended March 31, 2014 were $0.9 million as...

2014-05-01 08:31:31

NEW YORK, May 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the data from its multi-institutional post-approval trial of MuGard(®) that was recently published in Cancer, has been selected as a cover article in the premier publication. Cancer, the journal of the American Cancer Society is one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess...

2014-04-15 08:30:20

NEW YORK, April 15, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that positive results from a study conducted at Nova Southeastern University were presented recently at the Frontiers in Oral Medicine 2014 conference, hosted by the American Academy of Oral Medicine, in Orlando, Florida. The poster, entitled "Effectiveness of a Polymer-Based Muco-Adhesive (MuGard(®)) in the Healing of Oral Ulcers in Erosive Lichen...

2014-04-08 08:32:03

Additional Mucoadhesive Polymer Hydrogel Technology Formulation; Seeking Marketing Partners NEW YORK, April 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard(TM), for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved and used in the US, Japan and other countries,...

2014-04-07 08:29:57

PRINCETON, N.J., April 7, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded Soligenix a Small Business Innovation Research (SBIR) grant...

2014-04-01 08:29:19

Expanding Product Offerings; Building IP Portfolio; Seeking Global Marketing Partners NEW YORK, April 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and...

2014-03-26 08:29:22

Company Seeking Global Marketing Partners for its Proprietary Vitamin B-12 Drug Delivery Technology NEW YORK, March 26, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.